Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,901–13,000 of 15,747
Beyond the US-China biotech scoreboard
Yang, Y. T. (2026) · Science · doi:10.1126/science.aeg0560 · Cited by 1
(2024) · doi:10.1101/2024.07.23.24310889 · Cited by 1
“We defined onset of vaccine protection as 14 days after receipt of each dose, which is consistent with literature 28,29 .”
ResultSchmidt, K. G., Geißler, P., Schuster, E.-M., Schülein, C., Harrer, E. G., Schönau, V., Luber, M., Spriewald, B. M., Steininger, P. A., Bergmann, S., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111949 · Cited by 1
Balčiuvienė, V., Burčiuvienė, A., Haarhaus, M. L., et al. (2023) · Acta medica Lituanica · doi:10.15388/amed.2023.30.1.3 · Cited by 1
“Vaccination with BNT162b2 was well tolerated and safe, as it was reported in phase 3 clinical trials for BNT162b2 [16] and in most studies with ESRD patients.”
Measuring the Factors of Hesitancy in Saudi Population toward COVID-19 Vaccines
Attar, R. M. S., Karkashan, A., Abbas, B., Almarashi, A., & Hashem, T. (2021) · Academic Journal of Research and Scientific Publishing · doi:10.52132/ajrsp.e.2021.292
Iftikhar, R., & Zaidi, U. (2021) · National Journal of Health Sciences · doi:10.21089/njhs.61.0038 · Cited by 1
Visual communication in the management of a global health emergency
Pérez–Montoro, M. (2022) · doi:10.3145/indocs.2022.9 · Cited by 1
Current strategies and future perspectives in COVID-19 therapy
Aravind, S. R., Mathew, K. A., Madathil, B. K., Mini, S., & John, A. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89972-7.00011-8 · Cited by 1
Koshida, T., Gohda, T., Murakoshi, M., et al. (2026) · Nephrology · doi:10.1111/nep.70209 · Cited by 1
Goryaynov, S. V., & Gurova, O. Y. (2024) · Vaccines · doi:10.3390/vaccines12020130 · Cited by 1
Rubio‐Casillas, A., Redwan, E. M. M. M., & Uversky, V. N. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2025.02.001 · Cited by 2
Liakou, A. Ι., Tsantes, A. G., Bompou, E., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13030542 · Cited by 1
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was spread rapidly throughout the world in 2019–2020, resulting in the Coronavirus Disease (COVID-19) pandemic [1].”
Efektivitas Vaksinasi terhadap Tingkat Keparahan Covid-19
Fauziah, D. A., & Sari, D. N. (2023) · Jurnal Epidemiologi Kesehatan Indonesia · doi:10.7454/epidkes.v7i1.6374 · Cited by 1
Lee, G., Ryu, J., Jang, J., Noh, W., & Kim, D.-E. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkaf1536 · Cited by 3
Hussein, N. S., Al-Rayahi, I., Muhsin, S. S., & Alameer, R. A. K. (2023) · Journal of Techniques · doi:10.51173/jt.v5i2.1267 · Cited by 3
“Coronavirus Disease 2019 is brought on by the SARS-CoV-2 virus (COVID-19), and is susceptible to being prevented from spreading by messenger RNA (Pfizer) vaccinations [19-21].”
Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design
Sealy, R. E., Dayton, B. H., Finkelstein, D., & Hurwitz, J. L. (2021) · Viruses · doi:10.3390/v13050884 · Cited by 2
“During the past year, mRNA vaccines have emerged as attractive delivery vehicles for severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) vaccines [81,82].”
BackgroundThree Cases of Coronavirus Disease 2019 Vaccine-associated Organizing Pneumonia
Ono, T., Koyama, T., Notohara, K., et al. (2023) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000740 · Cited by 1
Wei, C. Y., Zhu, Y., Lu, X., Goodier, K. D., Yu, D., Liu, X., Choy, J., Calderón, A. T., Ma, J., Su, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.21.649878 · Cited by 1
“…in the Moderna COVID-19 vaccine 41 ), PBT (using the ALC-0315 as the ionizable lipid and same composition as in the Pfizer-BioNTech COVID-19 vaccine 42 , except DMG-PEG2000 as the PEGylated lipid), and ALN (used in the Alnylam Onpattro formulation 43 ), in addition to one LNP formulation DI-8,…”
Attitudes toward COVID-19 and Other Vaccines: Comparing Parents to Other Adults, September 2022
Dudley, M. Z., Schuh, H. B., Goryn, M., Shaw, J., & Salmon, D. A. (2023) · Vaccines · doi:10.3390/vaccines11121735 · Cited by 1
COVID-19 Vaccine Clinical Trials: A Bird’s Eye Perspective
Chennakesavulu, P. V., Cuddapah, G. V., Keesara, M. R., Inampudi, J. V., Arremsetty, A., Moka, S., & Miryala, S. (2022) · Cureus · doi:10.7759/cureus.28066 · Cited by 2
“reported that Phase-II/III trials had resulted in vaccine effectiveness of over 95% [10].”
BackgroundVarley, M., Euden, J., Adams, R., Barnes, E. J., Bodman, C., Choy, E., Cicconi, P., Dagley, V., Ewer, K., Griffin, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-084345 · Cited by 1
Mai, F., Reisinger, E. C., & Müller‐Hilke, B. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110523 · Cited by 1
Pandemic Viruses at Hajj: Influenza and COVID-19
Alfelali, M., Koul, P. A., & Rashid, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-36811-1_50 · Cited by 3
Yamaguchi, Y., Okochi, J., Urano, T., Ebihara, T., Kadono, T., Arai, H., Iijima, K., Ishii, S., Kuzuya, M., Rakugi, H., et al. (2023) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14700 · Cited by 1
Hirotsu, Y., Takatori, M., Mochizuki, H., & Omata, M. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100433 · Cited by 1
“COVID-19 mRNA vaccines induce a strong immune response against SARS-CoV-2 and are effective in reducing the risk of SARS-CoV-2 infection [7,8].”
BackgroundHigh COVID-19 transmission rates jeopardize global mass vaccination campaigns
Zuin, M., Zuliani, G., & Roncon, L. (2021) · Pathogens and Global Health · doi:10.1080/20477724.2021.1894042 · Cited by 1
Suzanna, S., Natosba, J., & Fatriansari, A. (2022) · Jurnal Aisyah Jurnal Ilmu Kesehatan · doi:10.30604/jika.v7i1.823 · Cited by 2
mRNA-lipid Nanoparticle Vaccines: Structure and Delivery
Cai, Y., Liao, J., & Tan, H. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.6269 · Cited by 1
Approaches to vaccination against the new coronavirus infection in solid organ recipients
Полищук, В. Б., Костинов, М. П., Ryzhov, A. A., Karchevskaya, N. A., Tarabrin, E. A., & Каллагов, Т. Э. (2022) · PULMONOLOGIYA · doi:10.18093/08690189-2022-32-2-239-243 · Cited by 1
Are allergic diseases a risk factor for systemic side effects after COVID-19 vaccines?Preprint
Atayık, E., & Aytekin, G. (2022) · medRxiv · doi:10.1101/2022.01.23.22269704 · Cited by 1
“It has been reported in many studies examining the side effects developed after COVID9 19 vaccines that the most common LSE caused by COVID-19 is pain at the injection 10 site, and the most common SSE is weakness/fatigue (7-11).”
BackgroundGreetings from the editor 2023/2
Smolen, J. S. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224301 · Cited by 1
Political economics in health and implications for neurosurgery diseases
Han, Y., & Huang, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1444249 · Cited by 1
Atopia e/ou angioedema no paciente com urticária colinérgica com revisão da literatura
Franco, G. R., Brandão, J. C., Pereira, G. D. F., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200050 · Cited by 1
The First Ethiopian Case Report of Post-COVID-19 Vaccine Associated Guillain-Barre Syndrome
Demissie, Z., Tesfaye, E., Bitew, A., Worku, A., & Haile, T. (2022) · doi:10.56558/journal.ejmscr.1001041 · Cited by 1
Causal analysis of absolute and relative risk reductions
Meder, B., Wu, C. M., & Rebitschek, F. G. (2025) · Journal of Mathematical Psychology · doi:10.1016/j.jmp.2025.102942 · Cited by 2
Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination
(2022) · doi:10.1101/2022.08.30.22279344 · Cited by 1
“The original two-dose BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine elicits antibodies that are highly effective at neutralizing the ancestral virus (Baden et al., 2021; Polack et al., 2020).”
BackgroundFarooq, M., Malik, M. F., Hussain, A., Latif, M., Rathore, M. U., & Lodhi, R. (2021) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v6i6.7034 · Cited by 1
Tanifuji, A., Ohfuji, S., Matsumoto, K., Abe, M., Komori, A., Takahashi, A., Kawata, K., Sato, K., Joshita, S., Umemura, T., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14018 · Cited by 2
“In terms of safety, the adverse reaction profile of the vaccines in this study was comparable to that in clinical trials on the general population 2,3 and the general Japanese population.”
ResultLei, H. (2025) · Viruses · doi:10.3390/v17081060 · Cited by 2
“As for vaccination, the rationale is that host response to vaccination is unlikely harmful to the body for the vast majority of vaccinated people [19,20].”
Burning Mouth Syndrome Following Covid Vaccination: A Case Report
Broachwala, M. Y., Banks, D., Jevotovsky, D. S., Oehlermarx, W., & Durbhakula, S. (2025) · Clinical Case Reports · doi:10.1002/ccr3.70329 · Cited by 1
Precision recruitment for high-risk participants in a COVID-19 cohort study
Mezlini, A. M., Caddigan, E., Shapiro, A. D., et al. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101113 · Cited by 1
Xu, J., Zheng, Z., Jiang, Y., Wang, Q., Dai, Z., Yuan, R., Yu, Z., Gong, Y., Hou, F., Ding, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5047616/v1 · Cited by 1
Sengupta, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00007-6 · Cited by 1
Guerini, A. E., Marvaso, G., Tonoli, S., Corrao, G., Teriaca, M. A., Sepulcri, M., Scricciolo, M., Gava, A., MONTRONE, S., Giaj‐Levra, N., et al. (2024) · Cancers · doi:10.3390/cancers17010086 · Cited by 1
Scapaticci, M., Bartolini, A., Vignoli, M., Orecchioni, C., Paradiso, M., Riga, M., Marzo, C., Corda, C., Costantini, S., Arnetoli, F., et al. (2023) · Infezioni in Medicina · doi:10.53854/liim-3104-10 · Cited by 1
Scanlon, B., Wyld, D., Firman, P., Nakagaki, M., Durham, J., Kennedy, G., Moran, P., Smith, M. E., & Gavin, N. (2022) · Australian Health Review · doi:10.1071/ah22142 · Cited by 1
SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study
Oliveira, K., Almeida, A., Silva, C., Brito, M., & Ribeiro, E. (2024) · Infectious Disease Reports · doi:10.3390/idr16060088 · Cited by 1
“BNT162b2 and mRNA-1273 are mRNA vaccines that use lipid nanoparticles to deliver mRNA that encodes for a pre-fusion stabilized SARS-CoV-2 Spike protein [24,25].”
Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series
Ammar, H., Beller, C. L., Bouccara, D., et al. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12942 · Cited by 1
“demonstrated high efficacy in preventing COVID-19 disease, by stimulating humoral and cellular immune responses against SARS-CoV-2, with an acceptable safety profile [7, 8].”
BackgroundSyncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
Altermanini, M., Habib, M. B., Alkhiyami, D. I., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18716 · Cited by 1
“One of the most common reported side effects was fever, and it was mainly observed after the second dose of BNT162b2 mRNA Covid-19 Vaccine within the first one to two days after vaccination [11].”
BackgroundYau, K., Chan, C. T., Abe, K. T., Jiang, Y., Atiquzzaman, M., Mullin, S. I., Shadowitz, E., Liu, L., Kostadinovic, E., Sukovic, T., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.211881-f · Cited by 1
“Antécédents de COVID‐19† 6 (4,6) 5 (5,3) 1,00”
Perrone, C., Schilling, W. H., Callery, J. J., Ashley, E. A., Chambers, M., Chase, H., Dahal, P., Kanthawang, N., Nedsuwan, S., Hanboonkunupakarn, B., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16880.1 · Cited by 1
Peng, Y., Yang, W., Zhou, Y., Fei, D., Kang, K., Meng, X., Zhao, M., Liu, X.-M., Yu, S., Luan, F., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12594 · Cited by 1
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics
Lee, J. H., Han, J., Park, S., & Mok, H. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70210 · Cited by 2
Bando, T., Ikematsu, H., Hamada, K., et al. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.102911 · Cited by 1
Rashid, M. R. A., Mohamad, S. N. S., Suria, A., & Shahra, R. (2022) · Cureus · doi:10.7759/cureus.22133 · Cited by 1
“Local reactions incidence did not increase after the second dose and was mostly mild-tomoderate and resolved within one to two days [6].”
BackgroundVaccine efficacy, safety, and regulatory controls
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00008-x · Cited by 1
Immunology in COVID-19; more than diagnosis of infection or the basis of vaccination
Egri, N., & Juan, M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.11.005 · Cited by 2
Peng, S., Lyu, L., Registre, L., Subedi, S., Mubassir, M. H. M., Bakheet, M., & Bahl, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1576414 · Cited by 1
Wang, L., Zhang, L., Zhang, T., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1420497 · Cited by 1
Niu, Z., Li, X., Gao, Y., Wang, L., Fan, S., Xu, X., Jiang, G., Cui, P., Li, D., Liao, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10121996 · Cited by 1
Medina, E., Sánchez-Sandoval, A. L., Barrón-Palma, E. V., Espinosa-García, A. M., Villalobos-Osnaya, A., León-Hernández, M., Hernández-Medel, M. L., Hernández-Ruiz, J., Medeiros-Domingo, M., Cedro‐Tanda, A., et al. (2024) · F1000Research · doi:10.12688/f1000research.143776.2 · Cited by 1
ХРОНИЧЕСКАЯ БОЛЕЗНЬ ПОЧЕК И COVID-19: СИСТЕМАТИЧЕСКИЙ ОБЗОР ЛИТЕРАТУРЫ
Гаражаева, Л. Ш., Gaipov, A., & Kauysheva, A. (2023) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2023.32.81.012 · Cited by 1
Risk Factors for SARS-CoV-2 Among a Cohort of Healthcare Workers in Lebanon
Sakr, C. J., Hassan, F. F. A., Fakih, L., Hamdan, M. B., Assaf, S. A., Rahme, D. V., & Melhem, N. M. (2023) · Workplace Health & Safety · doi:10.1177/21650799231214234 · Cited by 1
“The BNT162b2 mRNA COVID-19 vaccine, an mRNA vaccine encoding the SARS-CoV-2 full-length spike (S) protein (Polack et al., 2020), was the first administered vaccine in Lebanon.”
BackgroundThe Adverse Effects After COVID-19 Vaccination and Its Determinants among Adults in Kuala Terengganu
Idris, N. A., Yusof, N. A., Yunus, N. I., Daud, N., Juhari, S. N., Hassan, N. M., Mukhali, H. B., Pauzi, M. F., & Ismail, M. (2023) · Asian Journal of Medicine and Biomedicine · doi:10.37231/ajmb.2023.7.1.597 · Cited by 1
“The questionnaire was adapted from several sources 5,17,19,20 and consisted of three major sections: i) participants’ demographic data, ii) medical background and iii) self-reported AEs.”
MethodXu, J., Lim, A., & Rutherford, G. W. (2022) · Journal of Correctional Health Care · doi:10.1089/jchc.21.03.0024 · Cited by 1
Clar, M., Walker, A., & Solomon, P. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_126 · Cited by 1
Vaccine-elicited B and T cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H.-L., Aviszus, K., Zelarney, P., Liao, S.-Y., Gerber, A., Make, B., Wechsler, M., Marrack, P., & Reinhardt, R. (2023) · medRxiv · doi:10.1101/2023.01.25.23284971 · Cited by 1
Dmitrieva, K., Maslennikov, R. V., Vasilieva, E., Aliev, S., Bakhitov, V., Marcinkevich, V., Levshina, A., Kozlov, E. M., Ivashkin, V. T., & Poluektova, E. A. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.04.008 · Cited by 1
Wong, L. P., Lee, H. Y., Alias, H., Nguyen, D. K., Lachyan, A. S., Seheli, F. N., Ahmed, J., Hu, Z., & Lin, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2526231 · Cited by 1
“55,59,60 In addition to the potency, safety, and efficacy of mRNA vaccines that make them a formidable alternative to conventional vaccines, their ability for rapid clinical development and potential for low-cost manufacturing further enhance their strength.”
Zhang, Y., Zhang, J.-P., & Zhang, X.-B. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1838589 · Cited by 7
“Messenger RNA (mRNA) therapeutics have revolutionized modern medicine, a journey that began with the first proof-of-concept of in vivo expressed mRNA and culminated in the rapid deployment of COVID-19 vaccines (Wolff et al., 1990; Baden et al., 2021; Polack et al., 2020; Sahin et al., 2014).”
Chang, C.-C., Shi, L., Choi, S. H., Pennati, A., Valkanioti, V., Capitini, C. M., Mecozzi, S., & Galipeau, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.15.692195 · Cited by 1
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202523579 · Cited by 3
Kumar, N., & Susan, S. (2025) · Annals of Operations Research · doi:10.1007/s10479-025-06871-7 · Cited by 1
“It is set to 14 days based on the study (Polack et al., 2020).”
Vacunación contra coronavirus 2019 y estrés laboral en el personal de enfermería
Delgado-Valencia, C. A., Bárcenas-Hernández, B., Narváez-Velázquez, B., et al. (2022) · Revista CONAMED · doi:10.35366/108481 · Cited by 1
Gene Therapy for Inherited Metabolic Diseases
Longo, N., & Lai, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-94510-7_8 · Cited by 1
Schest, S., Langer, C., Stiegler, Y., Karnuth, B., Arends, J. P., Stiegler, H., Masetto, T., Peter, C., & Grimmler, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257265 · Cited by 1
Vicentini, C., Zotti, C. M., Cornio, A. R., Garlasco, J., Marengo, N., Meddis, D., Ditommaso, S., Giacomuzzi, M., Memoli, G., Bordino, V., et al. (2023) · Health Science Reports · doi:10.1002/hsr2.1087 · Cited by 1
“Clinical trials report these vaccines are both safe and effective.(6) In Italy, the vaccination campaign against SARS‐CoV‐2 began in December 2020, with the immunization offered initially to priority groups including healthcare”
BackgroundPasquale, C. D., Drommi, F., Calabrò, A., Botta, C., Migliore, G. S., Carrega, P., Vento, G., Gaeini, A., Pezzino, G., Freni, J., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.01.024 · Cited by 2
Shah, M., Moon, S. U., & Woo, H. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.30.424801 · Cited by 3
The Impacts of COVID-19 Vaccines on Mental Health Outcomes
Agrawal, V., Cantor, J., Sood, N., & Whaley, C. (2025) · American Journal of Health Economics · doi:10.1086/738494 · Cited by 1
A Case of Combination of IgA Nephropathy and Interstitial Nephritis After COVID-19 Vaccination
Yoshida, Y., Torigoe, K., Sakamoto, R., Abe, S., Muta, K., Mukae, H., & Nishino, T. (2024) · Cureus · doi:10.7759/cureus.52981 · Cited by 1
“Adverse events associated with mRNA-based COVID-19 vaccines commonly include injection site pain and fatigue, which are transient and do not constitute major problems [3].”
BackgroundÖztürk, D., Gareayaghi, N., Tahtasakal, C. A., Çalık, M., & Altınbilek, E. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02883-x · Cited by 1
“This difference is probably due to the different effectiveness of different vaccines produced on different platforms, and higher efficacies were detected after vaccination with the mRNA vaccines [24, 25].”
BackgroundYamamoto, C., Kobashi, Y., Kawamura, T., Nishikawa, Y., Saito, H., Oguro, F., Zhao, T., Takita, M., Sawano, T., Ozaki, A., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1406315 · Cited by 1
Sedaghat, M., Karami, B., Najafi, F., Shadmani, F. K., & Rezaeian, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126424 · Cited by 2
Khoury, S., Zoabi, Y., Scheinowitz, M., & Shomron, N. (2024) · Viruses · doi:10.3390/v16121864 · Cited by 1
“Recent trends show fewer sore throat cases with increased vaccine doses (Figure 13) [59], aligning with studies linking vaccine side effects to efficacy [6,7,60–62].”
InfluentialSARS-CoV-2 vs smallpox: mass vaccinations in the mirror
Bianucci, R., Nerlich, A. G., Cigliuti, E., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02723-x · Cited by 1
Lu, Z., Lu, Y., Liu, D., Du, F., Wu, Q., Liao, G., Wu, Y., Zhang, R., Zhou, J., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769155 · Cited by 4
Chu, J., Morikawa, H., & Chen, Y. (2023) · BioScience Trends · doi:10.5582/bst.2023.01012 · Cited by 1
YAMADA, T., & Ohwada, S. (2022) · The Kitakanto Medical Journal · doi:10.2974/kmj.72.87 · Cited by 1
Sheng, W., Wang, C., Chu, C.-C., Lin, Y., Chang, S., Ieong, S., & Chang, S. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.07.009 · Cited by 1
“The participants in the present study had similar incidences of laboratory abnormalities with these clinical trials.(4,8,10,11) This study had limitations.”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.